AGILYSYS INC
For the period ended Dec 31, 2025. Filed Jan 26, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Jan 26, 2026
AGYS$124.15+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. CONDENSED CONSOLIDATED BALANCE SHEETS
| (In thousands, except share data) | December 31,2025 (Unaudited) | March 31,2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $81,453 | $73,041 |
| Accounts receivable, net of allowance for expected credit losses of $780 and $627, respectively | 63,699 | 31,529 |
| Contract assets | 3,420 | 4,523 |
| Inventories | 7,794 | 5,174 |
| Prepaid expenses and other current assets | 13,407 | 9,260 |
| Total current assets | 169,773 | 123,527 |
| Property and equipment, net | 14,692 | 16,718 |
| Operating lease right-of-use assets | 14,903 | 17,114 |
| Goodwill | 135,845 | 130,640 |
| Intangible assets, net | 68,785 | 70,802 |
| Deferred income taxes, non-current | 60,519 | 66,520 |
| Other non-current assets | 10,661 | 9,049 |
| Total assets | $475,178 | $434,370 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $12,504 | $12,388 |
| Contract liabilities | 92,502 | 70,654 |
| Accrued liabilities | 19,472 | 22,324 |
| Operating lease liabilities, current | 5,423 | 5,658 |
| Total current liabilities | 129,901 | 111,024 |
| Deferred income taxes, non-current | 11,501 | 10,986 |
| Operating lease liabilities, non-current | 14,881 | 17,304 |
| Debt, non-current | — | 24,000 |
| Other non-current liabilities | 5,772 | 5,170 |
| Commitments and contingencies | ||
| Shareholders' equity: | ||
| Common shares, without par value, at $0.30 stated value; 80,000,000 shares authorized; 33,342,288 shares issued; and 28,097,684 and 28,015,775 shares outstanding at December 31, 2025 and March 31, 2025, respectively | 10,003 | 10,003 |
| Treasury shares, 5,244,604 and 5,326,513 at December 31, 2025 and March 31, 2025, respectively | (1,576) | (1,600) |
| Capital in excess of stated value | 125,719 | 109,785 |
| Retained earnings | 187,477 | 160,980 |
| Accumulated other comprehensive loss | (8,500) | (13,282) |
| Total shareholders' equity | 313,123 | 265,886 |
| Total liabilities and shareholders' equity | $475,178 | $434,370 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months EndedDecember 31, | Nine Months EndedDecember 31, | |||
|---|---|---|---|---|
| (In thousands, except per share data) | 2025 | 2024 | 2025 | 2024 |
| Net revenue: | ||||
| Products | $10,681 | $10,677 | $30,731 | $31,077 |
| Subscription and maintenance | 52,007 | 44,379 | 151,586 | 123,853 |
| Professional services | 17,702 | 14,505 | 54,049 | 46,422 |
| Total net revenue | 80,390 | 69,561 | 236,366 | 201,352 |
| Cost of goods sold: | ||||
| Products | 5,946 | 5,550 | 18,182 | 15,982 |
| Subscription and maintenance | 10,909 | 9,531 | 31,742 | 26,466 |
| Professional services | 13,293 | 10,625 | 39,938 | 31,967 |
| Total cost of goods sold | 30,148 | 25,706 | 89,862 | 74,415 |
| Gross profit | 50,242 | 43,855 | 146,504 | 126,937 |
| Gross profit margin | 62.5% | 63.0% | 62.0% | 63.0% |
| Operating expenses: | ||||
| Product development | 18,926 | 14,971 | 54,207 | 45,863 |
| Sales and marketing | 9,106 | 9,013 | 30,681 | 24,822 |
| General and administrative | 10,833 | 9,536 | 31,753 | 30,181 |
| Depreciation of fixed assets | 1,009 | 985 | 2,918 | 2,738 |
| Amortization of internal-use software and intangibles | 1,417 | 1,622 | 4,307 | 2,777 |
| Other (gains) charges, net | (2,717) | (12) | (7,923) | 2,576 |
| Legal settlements, net | (64) | 330 | 161 | 699 |
| Total operating expense | 38,510 | 36,445 | 116,104 | 109,656 |
| Operating income | 11,732 | 7,410 | 30,400 | 17,281 |
| Other income (expense): | ||||
| Interest income | 485 | 416 | 1,278 | 3,293 |
| Interest expense | (30) | (657) | (303) | (1,116) |
| Other income, net | 696 | 574 | 2,068 | 804 |
| Income before taxes | 12,883 | 7,743 | 33,443 | 20,262 |
| Income tax provision | 2,986 | 3,913 | 6,946 | 962 |
| Net income | $9,897 | $3,830 | $26,497 | $19,300 |
| Weighted average shares outstanding - basic | 27,970 | 27,667 | 27,882 | 27,446 |
| Net income per share - basic: | $0.35 | $0.14 | $0.95 | $0.70 |
| Weighted average shares outstanding - diluted | 28,438 | 28,314 | 28,379 | 28,248 |
| Net income per share - diluted: | $0.35 | $0.14 | $0.93 | $0.68 |
CONDENSED CONSOLIDATED STATE MENTS OF COMPREHENSIVE INCOME
| Three Months Ended · Nine Months Ended | ||||
|---|---|---|---|---|
| December 31, | December 31, | |||
| (In thousands) | 2025 | 2024 | 2025 | 2024 |
| Net income | $9,897 | $3,830 | $26,497 | $19,300 |
| Other comprehensive income (loss): | ||||
| Unrealized foreign currency translation adjustments | 1,597 | (10,049) | 4,782 | (9,498) |
| Total comprehensive income | $11,494 | $(6,219) | $31,279 | $9,802 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Nine Months Ended | ||
|---|---|---|
| December 31, | ||
| (In thousands) | 2025 | 2024 |
| Operating activities | ||
| Net income | $26,497 | $19,300 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Loss on asset disposals | 2 | 24 |
| Depreciation of fixed assets | 2,918 | 2,738 |
| Amortization of internal-use software and intangibles | 4,307 | 2,777 |
| Amortization of developed technology acquired | 498 | 301 |
| Deferred income taxes | 5,823 | (980) |
| Share-based compensation | 15,798 | 12,656 |
| Changes in operating assets and liabilities | (21,681) | (8,840) |
| Net cash provided by operating activities | 34,162 | 27,976 |
| Investing activities | ||
| Cash paid for business combination, net of cash acquired | — | (144,945) |
| Capital expenditures | (1,424) | (2,082) |
| Additional investments in corporate-owned life insurance policies | — | (27) |
| Net cash used in investing activities | (1,424) | (147,054) |
| Financing activities | ||
| Debt proceeds, net of issuance costs | — | 49,646 |
| Debt repayments | (24,000) | (12,000) |
| Proceeds from Employee Stock Purchase Plan purchases | 777 | 453 |
| Repurchase of common shares to satisfy employee tax withholding | (1,357) | (2,848) |
| Net cash (used in) provided by financing activities | (24,580) | 35,251 |
| Effect of exchange rate changes on cash | 254 | (303) |
| Net increase (decrease) in cash and cash equivalents | 8,412 | (84,130) |
| Cash and cash equivalents at beginning of period | 73,041 | 144,891 |
| Cash and cash equivalents at end of period | $81,453 | $60,761 |
CONDENSED CONSOLIDATED STATEM ENTS OF SHAREHOLDERS' EQUITY
| Common Shares | ||||||||
|---|---|---|---|---|---|---|---|---|
| Issued · In Treasury · Capital inexcess of · Accumulatedother | ||||||||
| (In thousands, except share data) | Shares | Statedvalue | Shares | Statedvalue | Statedvalue | Retainedearnings | comprehensiveincome (loss) | Total |
| Balance at September 30, 2025 | 33,342 | $10,003 | (5,300) | $(1,593) | $120,854 | $177,580 | $(10,097) | $296,747 |
| Share-based compensation | — | — | — | — | 5,579 | — | — | 5,579 |
| Shares issued upon exercise of SSARs | — | — | 18 | 6 | (6) | — | — | — |
| Shares withheld for taxes upon exercise of SSARs or vesting of other grants | — | — | (5) | (2) | (695) | — | — | (697) |
| Other common stock issuances, net | — | — | 42 | 13 | (13) | — | — | — |
| Net income | — | — | — | — | — | 9,897 | — | 9,897 |
| Unrealized translation adjustments | — | — | — | — | — | — | 1,597 | 1,597 |
| Balance at December 31, 2025 | 33,342 | $10,003 | (5,245) | $(1,576) | $125,719 | $187,477 | $(8,500) | $313,123 |
| Common Shares | ||||||||
| Issued · In Treasury · Capital inexcess of · Accumulatedother | ||||||||
| (In thousands, except share data) | Shares | Statedvalue | Shares | Statedvalue | Statedvalue | Retainedearnings | comprehensiveincome (loss) | Total |
| Balance at September 30, 2024 | 33,342 | $10,003 | (5,402) | $(1,622) | $102,275 | $153,225 | $(3,619) | $260,262 |
| Share-based compensation | — | — | — | — | 4,173 | — | — | 4,173 |
| Shares issued upon exercise of SSARs | — | — | 36 | 11 | (11) | — | — | — |
| Shares withheld for taxes upon exercise of SSARs or vesting of other grants | — | — | (12) | (4) | (1,421) | — | — | (1,425) |
| Other common stock issuances, net | — | — | (2) | (1) | 1 | — | — | — |
| Net income | — | — | — | — | — | 3,830 | — | 3,830 |
| Unrealized translation adjustments | — | — | — | — | — | — | (10,049) | (10,049) |
| Balance at December 31, 2024 | 33,342 | 10,003 | (5,380) | (1,616) | 105,017 | 157,055 | (13,668) | 256,791 |
| Common Shares | ||||||||
| Issued · In Treasury · Capital inexcess of · Accumulatedother | ||||||||
| (In thousands, except share data) | Shares | Statedvalue | Shares | Statedvalue | Statedvalue | Retainedearnings | comprehensiveincome (loss) | Total |
| Balance at March 31, 2025 | 33,342 | $10,003 | (5,327) | $(1,600) | $109,785 | $160,980 | $(13,282) | $265,886 |
| Share-based compensation | — | — | — | — | 15,803 | — | — | 15,803 |
| Shares issued upon exercise of SSARs | — | — | 37 | 11 | (11) | — | — | — |
| Shares withheld for taxes upon exercise of SSARs or vesting of other grants | — | — | (7) | (3) | (619) | — | — | (622) |
| Other common stock issuances, net | — | — | 52 | 16 | 761 | — | — | 777 |
| Net income | — | — | — | — | — | 26,497 | — | 26,497 |
| Unrealized translation adjustments | — | — | — | — | — | — | 4,782 | 4,782 |
| Balance at December 31, 2025 | 33,342 | $10,003 | (5,245) | $(1,576) | $125,719 | $187,477 | $(8,500) | $313,123 |
| Common Shares | ||||||||
| Issued · In Treasury · Capital inexcess of · Accumulatedother | ||||||||
| (In thousands, except share data) | Shares | Statedvalue | Shares | Statedvalue | Statedvalue | Retainedearnings | comprehensiveincome (loss) | Total |
| Balance at March 31, 2024 | 33,342 | $10,003 | (5,965) | $(1,791) | $94,680 | $137,755 | $(4,170) | $236,477 |
| Share-based compensation | — | — | — | — | 12,900 | — | — | 12,900 |
| Shares issued upon exercise of SSARs | — | — | 581 | 175 | (175) | — | — | — |
| Shares withheld for taxes upon exercise of SSARs or vesting of other grants | — | — | (28) | (9) | (2,832) | — | — | (2,841) |
| Other common stock issuances, net | — | — | 32 | 9 | 444 | — | — | 453 |
| Net income | — | — | — | — | — | 19,300 | — | 19,300 |
| Unrealized translation adjustments | — | — | — | — | — | — | (9,498) | (9,498) |
| Balance at December 31, 2024 | 33,342 | 10,003 | (5,380) | (1,616) | 105,017 | 157,055 | (13,668) | 256,791 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.